


**Multiple Treatment Interruptions and Protecting HIV-Specific CD4  
T-Cells Enables Durable CTL Response and Viral Control**

Supplementary data



**Figure S1: Comparison of AGT103-T cells detected by two independent methods.** (A-F) AGT103-T cells detected at various timepoints during the study by two independent methods, qPCR and amplicon-sequencing in six study participants were plotted against the number of days (x-axis) and the viral load (black). The q-PCR method detected WPRE normalized against housekeeping RPL32 (red) and amplicon-seq detected the ratio of modified miR30 to native miR30 (green). The cell counts are plotted on the left-hand Y-axis while the VL is reported on the right-hand Y-axis. The solid black line indicates the VL during the ATI and the dashed black line represents the VL on ART.

**Table S1: AGT103-T cells as a proportion of circulating CD4 T cells relative to the dose and duration between the infusion and the initiation of the ATI.**

<b>Patient ID</b>	<b>Infused Product Dose</b>	<b>Days between Infusion and the Start of ATI-1</b>	<b>AGT103-T (% of total CD4) at the Start of ATI-1</b>
01-008	1.67 E+9	150	0.544
02-009	1.38 E+9	99	0.220
01-002	0.192 E+9	490	0.026
02-001	0.62 E+9	246	0.008
01-005	0.46 E+9	411	0.003
01-007	0.19 E+9	390	0.009